Author's response to the commentary: Neuromyelitis optica complicating COVID vaccinations and additional case reports
N Tisavipat, C Anamnart, W Owattanapanich… - Multiple Sclerosis and …, 2022 - Elsevier
N Tisavipat, C Anamnart, W Owattanapanich, M Apiwattanakul, P Savangned…
Multiple Sclerosis and Related Disorders, 2022•ElsevierOur article Newly diagnosed neuromyelitis optica spectrum disorders following vaccination:
Case report and systematic review had instigated a critique that there were more cases of
post-COVID-19-vaccination NMOSD. Indeed, after the systematic review was performed in
July 2021, many reports have been published, and we have seen two new patients at our
center as well. However, Finsterer's question on the subclinical activity of NMOSD prior to
vaccination, although an interesting notion, was debatable. NMOSD is a relapsing disease …
Case report and systematic review had instigated a critique that there were more cases of
post-COVID-19-vaccination NMOSD. Indeed, after the systematic review was performed in
July 2021, many reports have been published, and we have seen two new patients at our
center as well. However, Finsterer's question on the subclinical activity of NMOSD prior to
vaccination, although an interesting notion, was debatable. NMOSD is a relapsing disease …
Summary
Our article Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review had instigated a critique that there were more cases of post-COVID-19-vaccination NMOSD. Indeed, after the systematic review was performed in July 2021, many reports have been published, and we have seen two new patients at our center as well. However, Finsterer's question on the subclinical activity of NMOSD prior to vaccination, although an interesting notion, was debatable. NMOSD is a relapsing disease with severe attacks. Investigations in our patients did not reveal robust evidence of prior subclinical attacks so far.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果